Scientists Develop First Small-Molecule Activators for Heart-Protective PAK1 Kinase

This groundbreaking study represents a significant advance in therapeutic development, as kinase activators are notoriously difficult to create compared to kinase inhibitors. The research focused on PAK1 (p21-activated kinase-1), a critical regulator of cardiac homeostasis that becomes dysregulated in heart disease.

The Oxford-led team used an innovative rational peptide-guided strategy to target PAK1's autoinhibitory regulation. They discovered a previously unknown autoinhibition-release site between the autoregulatory region and kinase domain, providing a new therapeutic target. Through high-throughput screening and medicinal chemistry optimization, they developed selective allosteric activators with micromolar potency and isoform selectivity.

Structural and mechanistic analyses revealed that these activators work by disrupting PAK1's natural self-inhibition, promoting both local and global conformational transitions that shift the kinase to its active state. This enhanced activity was confirmed in cardiac cells through improved PAK1 signaling pathways.

Most importantly, in vivo studies demonstrated therapeutic efficacy in animal models of both inherited and acquired cardiac hypertrophy. The compounds showed promise for treating heart conditions where enhanced PAK1 activity could restore normal cardiac function and prevent pathological remodeling.

This work establishes rational modulation of kinase autoinhibitory regulation as a viable strategy for discovering kinase activators, a largely unexplored area with significant therapeutic potential beyond cardiology.